What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

NephroNet

Name: NephroNet
Address: Lawrenceville, GA, US
Telephone: +17704909203
Price range: $

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from NephroNet, Market Research Consultant, Lawrenceville, GA.

NephroNet is a network of dedicated clinicians, investigators and affiliated sponsors that are collectively committed to advancing patient education, research and the realization of new methods to treat kidney disease.

08/31/2026

💬 Reducing Therapeutic Nihilism in Chronic Kidney Disease (CKD)
Far too often, patients with CKD are told what can’t be done rather than what can.
This editorial challenges that mindset — urging clinicians to move beyond therapeutic nihilism and embrace proactive, evidence-based management for kidney disease.
🩺 The message is clear:
➡️ CKD is not a lost cause.
➡️ Early intervention and personalized care can make a meaningful difference.
➡️ Empowerment and optimism must guide treatment strategies.
Read the full editorial in British Journal of Hospital Medicine:
📖 “Reducing Therapeutic Nihilism in Patients With Chronic Kidney Disease”

https://pubmed.ncbi.nlm.nih.gov/41134164/

08/27/2026

🧠 New Research Insight: Steroid Withdrawal After Pancreas-Kidney Transplant
Can steroids safely be withdrawn after simultaneous pancreas-kidney (SPK) transplantation?
A study of 307 SPK recipients found:
✅ No difference in rejection rates between steroid-withdrawal and steroid-maintenance groups (26% vs. 29%)
✅ Long-term outcomes were driven by rejection, not by steroid regimen
✅ Kidney rejection strongly predicted both kidney and pancreas graft survival
✅ Obesity was linked to higher risk of pancreas graft failure
🔍 Takeaway: For low-risk SPK recipients, early steroid withdrawal appears safe, with careful monitoring and individualized management.

https://pubmed.ncbi.nlm.nih.gov/41134310/

08/23/2026

💡 New Study on Type 2 Diabetes and Lifestyle Habits
A nationwide analysis of 119,000+ U.S. adults with Type 2 diabetes reveals an important truth:
🏃‍♀️ Even some physical activity and healthy eating go a long way.
📊 Key Findings:
• 37% of patients were physically inactive
• 53% ate ≤2 servings of fruits/vegetables daily
• Yet, even limited physical activity greatly improved:
✅ Self-rated health
✅ Cardiovascular outcomes
✅ Kidney health
👉 The takeaway: You don’t need to be perfect — small, consistent lifestyle improvements make a measurable difference.

https://pubmed.ncbi.nlm.nih.gov/41134496/

________________________________________
Twitter / X (≤280 characters)
🏃‍♂️💚 New study of 119K+ Americans with Type 2 diabetes shows:
Even modest physical activity = big health gains.
Inactive → “Good health” ↑ 2.6× with regular movement.
Perfection isn’t required—progress matters.

https://pubmed.ncbi.nlm.nih.gov/41134496/

08/20/2026

🧠🩺 New Study Insight:
Urinary tract infections (UTIs) remain the most common post-transplant infection—but not all kidney transplant centers perform equally.
A review of 5,128 patients across 25 U.S. centers found UTI rates ranging from 0% to 12.9% within 30 days after surgery.
Key risk factors:
• Use of ureteral stents
• Longer catheter duration
• Female gender
• Older recipient age
➡️ The findings underscore the need for center-level collaboration to reduce complications and improve outcomes.

https://pubmed.ncbi.nlm.nih.gov/41134503/

08/18/2026

🧬 Nanotechnology Meets Cancer Detection!
A groundbreaking study explores how biomolecular coronas (BCs) — the unique protein layers that form around nanoparticles in the bloodstream — could be harnessed for early cancer diagnosis.
Researchers analyzed surface-modified polystyrene and silica nanoparticles with diverse functional groups (plain, NH₂, COOH) and found that BC signatures could distinguish healthy individuals from patients with cancer, and even differentiate cancer types such as ovarian and kidney cancer.
💡 Why it matters:
This fast, inexpensive, and minimally invasive method — requiring only a simple blood sample — could pave the way for personalized, first-line cancer diagnostics and post-treatment monitoring.
🧪 Study: “Study of the biomolecular corona of surface-modified polystyrene and silica nanoparticles: application to cancer.”

https://pubmed.ncbi.nlm.nih.gov/41134530/

08/14/2026

🫀 New Insights from the CARE-HK in HF Registry
Managing patients with heart failure (HF) at high risk of hyperkalaemia remains a global challenge. The CARE-HK in HF multinational registry provides a detailed look at how these patients are managed in real-world clinical settings.
📊 Key Findings:
• 2,558 patients across 9 countries and 111 sites were followed prospectively
• 29% experienced a hyperkalaemic event during follow-up
• Only 29% received optimal RASi/MRA therapy, despite guideline recommendations
• Potassium binder use was limited (patiromer 9.1%, SZC 5.9%)
• Hyperkalaemia was associated with higher hospitalization risk (HR 1.59; p < 0.001)
💡 Conclusion: Hyperkalaemic events in HF are common and under-managed, leading to suboptimal therapy and increased hospitalizations. The registry highlights an urgent need for strategies to safely optimize RASi/MRA treatment in this population.
🔗 CARE-HK in HF Registry – ClinicalTrials.gov: [NCT04864795]

https://pubmed.ncbi.nlm.nih.gov/40788620/

08/11/2026

🧠 Designing Clinical Trials for the Treatment of Membranous Nephropathy in the PLA2R Era
Membranous nephropathy (MN) is a leading cause of adult nephrotic syndrome — and with the discovery of the phospholipase A2 receptor 1 (PLA2R) autoantigen, nephrology has entered a new era of precision medicine.
The NephCure Membranous Nephropathy Workshop brought together top nephrologists, researchers, and industry leaders to chart the path forward for MN drug development.
🔬 Key Highlights:
• PLA2R autoantibodies are present in ~75% of MN patients
• The discovery enables personalized diagnostics, monitoring, and trial design
• Experts emphasized the integration of PLA2R biomarkers into future clinical trial endpoints
• Collaboration among academia, regulators, and patient advocacy groups is key to accelerating treatment innovation
💡 Precision nephrology is redefining how we design, test, and deliver therapies for autoimmune kidney diseases.

https://pubmed.ncbi.nlm.nih.gov/40092585/

08/06/2026

🧬 Clinical Trial Spotlight: New Insights for Fibrillary Glomerulopathy (FGN)
Fibrillary glomerulopathy is a rare kidney disease that can lead to end-stage renal disease in up to half of patients within two years. The FACT trial evaluated the efficacy and safety of repository corticotropin (Acthar® Gel) alone or in combination with tacrolimus in DNA-JB9 positive FGN.
📊 Key Findings:
• Acthar Gel alone significantly reduced proteinuria by >70% at 12 months (from 6.21 to 1.76 g/g; P < 0.02)
• Adding tacrolimus did not provide additional benefit in reducing proteinuria or improving eGFR
• Both regimens were well tolerated over the 12-month treatment period
✅ Conclusion: Acthar Gel represents an effective antiproteinuric therapy for patients with DNA-JB9 positive FGN—offering hope for an ultra-rare condition with limited treatment options.

https://pubmed.ncbi.nlm.nih.gov/40980649/

07/31/2026

💊 Clinical Research Update: Promising Results in IgA Nephropathy Treatment
A new multinational phase 3 trial shows that atrasentan, a selective endothelin type A receptor antagonist, significantly reduced proteinuria by 36% compared to placebo in patients with biopsy-proven IgA nephropathy — a condition linked to a high lifetime risk of kidney failure.
Importantly, atrasentan demonstrated strong efficacy and a favorable safety profile, with no reported cases of cardiac failure or severe edema.
🧠 These findings highlight the potential of atrasentan to become a meaningful therapeutic advancement for patients with severe proteinuria.
🔗 Learn more about the ALIGN study (NCT04573478) and the future of precision nephrology.

https://pubmed.ncbi.nlm.nih.gov/39460694/

07/30/2026

🔮 Nefecon Predicted to Delay Kidney Failure in IgA Nephropathy 🧬

A modeling analysis based on Phase 3 NefIgArd data suggests nefecon could delay progression to kidney failure by up to 12.8 years in patients with IgA nephropathy.
📉 62% reduction in risk of major kidney outcomes
🧪 Median time to kidney failure:
• 22.4 years with nefecon
• 9.6 years with supportive care only
These results highlight nefecon’s long-term potential in preserving kidney function.

🔗 Learn more: https://ow.ly/Eufm50X4AaY

Address

Lawrenceville, GA

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+17704909203

Website

http://www.nephronet.org/

Alerts

Be the first to know and let us send you an email when NephroNet posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Advertising & Marketing Company in Lawrenceville?